www.eurekatherapeutics.com Open in urlscan Pro
162.144.14.104  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * 

 * About
 * Technology
   * E-ALPHA® Phage Display Platform
   * ARTEMIS® Cell Receptor Platform
   * ARTEMIS® T-Cell Therapy
   * Scientific publications
 * Pipeline
 * Patients
 * Press
 * Careers
 *  Accessibility




HARNESSING THE EVOLUTIONARY POWER OF


T CELLS TO FIGHT SOLID TUMORS


HARNESSING THE EVOLUTIONARY POWER OF T CELLS TO FIGHT SOLID TUMORS


WHO WE ARE

Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company
developing transformative technology platforms that can access cancer-specific
targets and harness the evolutionary power of T cells for the treatment of solid
tumors and other malignancies.

MORE ABOUT EUREKA



TWO PROPRIETARY PLATFORMS


E-ALPHA®

Leveraging high-throughput
screening to develop cancer-
specific antibodies.

artemis-science


ARTEMIS®

Harnessing the
evolutionary power of
T cells to fight cancer.

EXPLORE THE PLATFORMS


OUR PIPELINE HIGHLIGHTS THE UNLIMITED POTENTIAL OF THE ARTEMIS AND E-ALPHA
PLATFORMS TO TRANSFORM THE TREATMENT OF CANCER.


CANCER INDICATION

 * DISCOVERY
 * PRECLINICAL
 * PHASE I/II
 * PHASE III

TRAVERSE THE PIPELINE


THE EUREKA THERAPEUTICS® APPROACH TO FIGHTING SOLID TUMORS IS TO DEVELOP
MULTIPLE POTENTIAL TREATMENT OPTIONS FOR PATIENTS BY CULTIVATING A DEEPER
UNDERSTANDING OF EACH TYPE OF CANCER AND LEVERAGING OUR CUTTING-EDGE TECHNOLOGY
PLATFORMS.

CURRENT CLINICAL TRIALS



NEWS UPDATE

2021
01 November 2021
Imugene and Eureka Therapeutics Announce Strategic Collaboration to Accelerate
Advancement of Oncolytic Virus and T-Cell Therapy in Solid Tumours
2021
21 July 2021
Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of
GPC3 Targeting ARTEMIS® T Cell Therapy in Liver Cancer
2021
16 July 2021
Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target
Multiple Myeloma
2020
14 December 2020
Eureka Therapeutics Announces Successful Preclinical Results of InvisiMask™
Human Antibody Nasal Spray Against SARS-CoV-2 Infection
2020
09 November 2020
Eureka Therapeutics Appoints Nobel Laureate Randy Schekman, Ph.D. to its
Scientific Advisory Board
2020
13 October 2020
Eureka Therapeutics to Present at Two Upcoming Virtual Conferences
Press releases
18 October 2022
Eureka Therapeutics Announces License with the National Cancer Institute to
Advance GPC2 ARTEMIS® T Cell Therapy for Neuroblastoma
Press releases
17 October 2022
Eureka Therapeutics Receives Orphan Drug Designations for Treatment of
Hepatoblastoma with ET140203 ARTEMIS® T cells
Press releases
03 August 2022
Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic
Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer
Press releases
25 April 2022
Eureka Therapeutics to Present at the 18th Annual PEGS Boston Conference and
Expo
2022
08 February 2022
Eureka Therapeutics Receives Orphan Drug Designations for Treatment of
Hepatocellular Carcinoma (HCC) with ARTEMIS® T cells
2021
17 November 2021
Eureka Therapeutics Announces Initiation of Phase I/II ARYA-2 Clinical Trial of
ET140203 ARTEMIS® T Cells to Treat Pediatric Liver Cancer
2021
01 November 2021
Imugene and Eureka Therapeutics Announce Strategic Collaboration to Accelerate
Advancement of Oncolytic Virus and T-Cell Therapy in Solid Tumours
2021
21 July 2021
Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of
GPC3 Targeting ARTEMIS® T Cell Therapy in Liver Cancer
2021
16 July 2021
Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target
Multiple Myeloma
2020
14 December 2020
Eureka Therapeutics Announces Successful Preclinical Results of InvisiMask™
Human Antibody Nasal Spray Against SARS-CoV-2 Infection
2020
09 November 2020
Eureka Therapeutics Appoints Nobel Laureate Randy Schekman, Ph.D. to its
Scientific Advisory Board
2020
13 October 2020
Eureka Therapeutics to Present at Two Upcoming Virtual Conferences
Press releases
18 October 2022
Eureka Therapeutics Announces License with the National Cancer Institute to
Advance GPC2 ARTEMIS® T Cell Therapy for Neuroblastoma
Press releases
17 October 2022
Eureka Therapeutics Receives Orphan Drug Designations for Treatment of
Hepatoblastoma with ET140203 ARTEMIS® T cells
Press releases
03 August 2022
Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic
Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer
Press releases
25 April 2022
Eureka Therapeutics to Present at the 18th Annual PEGS Boston Conference and
Expo
2022
08 February 2022
Eureka Therapeutics Receives Orphan Drug Designations for Treatment of
Hepatocellular Carcinoma (HCC) with ARTEMIS® T cells
2021
17 November 2021
Eureka Therapeutics Announces Initiation of Phase I/II ARYA-2 Clinical Trial of
ET140203 ARTEMIS® T Cells to Treat Pediatric Liver Cancer


MORE EUREKA NEWS


CAREERS


AT EUREKA, WE BELIEVE THAT THE HIGHEST PERFORMING TEAMS INCLUDE PEOPLE FROM A
WIDE VARIETY OF BACKGROUNDS AND EXPERIENCES.

JOIN OUR TEAM
 * Contact us
 * Terms & Conditions/Privacy Policy

Menu
 * Contact us
 * Terms & Conditions/Privacy Policy

EUREKA THERAPEUTICS, ARTEMIS, and E-ALPHA are registered trademarks owned by
Eureka Therapeutics, Inc.
© 2022 Eureka Therapeutics, Inc. All rights reserved


Facebook Twitter Linkedin Youtube